2 Top Stocks to Double Up on Right Now

Amazon's North American adjusted operating income climbed 28% last quarter on an 11% sales increase, driven by heavy automation (over 1 million in-house robots coordinated by DeepFleet), AI-enabled ad tools and 24% growth in high‑margin sponsored ads; AWS revenue is accelerating amid capacity constraints and sizable capex to expand AI data‑center footprint, and the stock trades below 30x 2026 analyst EPS. Philip Morris, up roughly 35% year‑to‑date but off its highs, is seeing smokeless growth power results—U.S. Zyn shipments rose 37% and retail offtake 39% last quarter, global non‑Nordic shipments more than doubled, and Iqos volumes grew 15.5% in Q3—while trading at under ~19.5x 2026 EPS with a PEG of ~0.85 and awaiting FDA approval for its Iluma system for a U.S. relaunch.

Analysis

Market structure: Amazon (AMZN) benefits directly from e-commerce operating leverage (NA OpInc +28% on +11% sales) and AWS AI demand; Philip Morris (PM) benefits from smokeless (Zyn +37% US shipments) and Iqos international growth. Losers include low-tech retail peers (WMT/COST) and third‑party logistics providers facing price pressure; energy and specialized chip suppliers see rising demand as AMZN capex ramps. Cross-asset: stronger AMZN growth expectations can steepen the yield curve (higher long-end rates) and lift NVDA implied vols; PM’s FX exposure makes USD strength a 3–5% EPS swing risk next 12 months.

Risk assessment: Tail risks include FDA rejection/delay of Iluma (10–25% EPS hit over 12–18 months), antitrust scrutiny of AWS/ads leading to revenue multiple compression (800–1,200 bps downside to growth multiples), and an AI hardware shortage that could cap AWS expansion next 6–12 months. Near-term (days/weeks) risks: earnings/capex updates and FDA filing timelines; medium-term (3–12 months): product rollouts and capacity additions; long-term (1–3 years): automation-driven margin re-rating. Hidden deps: AMZN’s productivity gains depend on DeepFleet efficacy and power costs; PM’s margin mix hinges on pouch vs cigarette mix shift rates.

Trade implications: Direct plays — establish sized long exposure to capture AWS/automation tailwinds (AMZN) and to PM’s smokeless margin upgrade, using staggered entries tied to explicit triggers (quarterly metrics, FDA milestones). Pair trades — long AMZN vs short WMT to express structural e‑commerce advantage while hedging consumer traffic risk. Options — use 9–18 month call spreads on AMZN to limit spend and 6–12 month bullish call spreads on PM ahead of Iluma readouts; buy protective puts if PM’s FDA timeline slips beyond 6 months.

Contrarian angles: The market may underprice AMZN’s internal robot IP and potential monetization/licensing upside and overprice PM’s U.S. Iluma path dependency; both create asymmetric outcomes. Historical parallel: automation rollouts (retail/warehouse) delivered multi-year margin expansion but required 12–24 months to realize — expect lumpy quarters. Action thresholds: add to AMZN on a 10% pullback or confirmed AWS >30% YoY revenue growth; cut PM by 50% if FDA rejection or >6‑month approval delay.

Key Decisions for Investors

• Establish a 3% long position in AMZN equity now to capture e-commerce operating leverage and AWS upside; complement with a 12‑18 month call spread (buy 5% ITM call, sell 25% OTM call) sized to an additional 2% notional to limit cash outlay. Add another 3% if AMZN falls >10% within 3 months or if AWS revenue growth >30% YoY in a quarterly print.
• Initiate a 2.5% long position in PM using stock or a 9–12 month bullish call spread (pay limited premium); increase to 5% on either FDA approval of Iluma or if Zyn US shipments accelerate to >40% YoY. Reduce position to 1% (or hedge with puts) if FDA decision is delayed >6 months or offtake growth falls below 10% YoY.
• Implement a pair trade: long AMZN (3% exposure) vs short WMT (2% exposure) for 6–12 months to express structural share shift to online/AI-driven advertising; rebalance if relative performance diverges >8% in either direction.
• Allocate 1% of portfolio to volatility-defined option protection: buy 9–12 month protective puts on PM (strike ~10% OTM) to cap tail loss from an FDA setback, and buy 12–18 month LEAP calls on AMZN (~25–40% OTM) as a low-cost asymmetric bet on AWS acceleration.